Replies to post #178164 on Cytodyn Inc (CYDY)

[kgromax]

I am a statistician and i know exactly what the DSMC said upon the CD12 interim.

It was bad.

But there is a common misunderstanding among longs that the DSMC gave the green light to pursue the trial so « they were positive about it ». It’s wrong.

So to kill this misconception once and for all, could you state in a couple words what you have understood of the DSMC answer and what it meant for the trial?

Then I can tell you the subtlety and why it was bad. Statisticians stuff…

[that_little_voice]

Right again but not realizing THE REALITY

Just look at the PR CYDY put out. Notice how Nader/Kelly omitted "stop the trial because no chance of hitting endpoint"? instead THE ONLY SAY "STOP TRIAL BECUASE OF SAFETY" Everyone knows LL is safe which is another red flag for its MOA. Notice how they avoided the DSMC recommendation for second review? They gave a BS response about not following recommendation for time efficiency. Just like Nader claim that the fda not wanting a meeting and instead have a phone call is actually better. They avoided the review from DSMC because then they would have to issue the results that the trial was going to fail ( which it did do to lack of PHase3 in US) AND NOW TRYING FOR EVERY EMERGING MARKET UNDER THE SUN.


https://www.cytodyn.com/newsroom/press-releases/detail/477/cytodyn-receives-positive-dsmc-recommendation-after-interim

Noticed THIS GEM, WHATEVER HAPPEND TO ALL THE BS ABOUT MHRA?

Clinical trial sites in the U.K. are expected to initiate enrollment in the coming days.